Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-6-21
pubmed:abstractText
The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications. We mined the US Food and Drug Administration's (FDA's) Adverse Event Reporting System (AERS) for side-effect profiles involving glucose homeostasis and found a surprisingly strong signal for comedication with pravastatin and paroxetine. We retrospectively evaluated changes in blood glucose in 104 patients with diabetes and 135 without diabetes who had received comedication with these two drugs, using data in electronic medical record (EMR) systems of three geographically distinct sites. We assessed the mean random blood glucose levels before and after treatment with the drugs. We found that pravastatin and paroxetine, when administered together, had a synergistic effect on blood glucose. The average increase was 19 mg/dl (1.0 mmol/l) overall, and in those with diabetes it was 48 mg/dl (2.7 mmol/l). In contrast, neither drug administered singly was associated with such changes in glucose levels. An increase in glucose levels is not a general effect of combined therapy with selective serotonin reuptake inhibitors (SSRIs) and statins.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1532-6535
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-42
pubmed:dateRevised
2011-10-11
pubmed:meshHeading
pubmed-meshheading:21613990-Adverse Drug Reaction Reporting Systems, pubmed-meshheading:21613990-Age Factors, pubmed-meshheading:21613990-Aged, pubmed-meshheading:21613990-Algorithms, pubmed-meshheading:21613990-Blood Glucose, pubmed-meshheading:21613990-Cohort Studies, pubmed-meshheading:21613990-Data Mining, pubmed-meshheading:21613990-Diabetes Mellitus, pubmed-meshheading:21613990-Drug Interactions, pubmed-meshheading:21613990-Electronic Health Records, pubmed-meshheading:21613990-Ethnic Groups, pubmed-meshheading:21613990-Female, pubmed-meshheading:21613990-Homeostasis, pubmed-meshheading:21613990-Humans, pubmed-meshheading:21613990-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:21613990-Male, pubmed-meshheading:21613990-Middle Aged, pubmed-meshheading:21613990-Paroxetine, pubmed-meshheading:21613990-Pravastatin, pubmed-meshheading:21613990-Retrospective Studies, pubmed-meshheading:21613990-Serotonin Uptake Inhibitors, pubmed-meshheading:21613990-Sex Factors, pubmed-meshheading:21613990-Socioeconomic Factors, pubmed-meshheading:21613990-United States, pubmed-meshheading:21613990-United States Food and Drug Administration
pubmed:year
2011
pubmed:articleTitle
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.
pubmed:affiliation
Biomedical Informatics Training Program, Stanford University, Stanford, California, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Multicenter Study, Research Support, N.I.H., Extramural